haloperidol has been researched along with Metabolic Diseases in 5 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Pérez-Iglesias, R | 1 |
| Martínez-García, O | 1 |
| Pardo-Garcia, G | 1 |
| Amado, JA | 1 |
| Garcia-Unzueta, MT | 1 |
| Tabares-Seisdedos, R | 1 |
| Crespo-Facorro, B | 1 |
| Fabrazzo, M | 1 |
| Monteleone, P | 1 |
| Prisco, V | 1 |
| Perris, F | 1 |
| Catapano, F | 1 |
| Tortorella, A | 1 |
| Monteleone, AM | 1 |
| Steardo, L | 1 |
| Maj, M | 1 |
| Nadaoka, T | 1 |
| Busch, KT | 1 |
| Schulz, H | 1 |
1 review available for haloperidol and Metabolic Diseases
| Article | Year |
|---|---|
[Acute confusional state (non alcoholic)].
Topics: Acute Disease; Antiparkinson Agents; Antipsychotic Agents; Central Nervous System Diseases; Confusio | 2003 |
1 trial available for haloperidol and Metabolic Diseases
| Article | Year |
|---|---|
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
3 other studies available for haloperidol and Metabolic Diseases
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Olanzapine Is Faster than Haloperidol in Inducing Metabolic Abnormalities in Schizophrenic and Bipolar Patients.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Female; Follow | 2015 |
[The acute psychiatric emergency].
Topics: Acute Disease; Aged; Alcoholism; Amitriptyline; Brain Ischemia; Cognition Disorders; Consciousness D | 1981 |